Merck 경영진

경영진 기준 점검 3/4

Merck CEO는 Rob Davis, Apr2021 에 임명되었습니다 의 임기는 4.92 년입니다. 총 연간 보상은 $23.19M, 7% 급여 및 93% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $51.54M 가치에 해당하는 회사 주식의 0.018% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.2 년과 6.5 년입니다.

핵심 정보

Rob Davis

최고경영자

US$23.2m

총 보수

CEO 급여 비율	7.00%
CEO 재임 기간	4.9yrs
CEO 지분 보유율	0.02%
경영진 평균 재임 기간	5.2yrs
이사회 평균 재임 기간	6.5yrs

최근 경영진 업데이트

Recent updates

The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff

Jan 30Merck’s 2026 narrative is a high-stakes drama centered on Keytruda , the world’s top-selling cancer drug. For years, the market has treated Merck like a "one-trick pony" due to the looming 2028 "patent cliff," where Keytruda will lose its legal protection and face generic competition.

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85

Dec 02

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Nov 02

Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality

Aug 12

CEO 보수 분석

Rob Davis의 보수는 Merck의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Dec 31 2025	n/a	n/a	US$18b
Sep 30 2025	n/a	n/a	US$19b
Jun 30 2025	n/a	n/a	US$16b
Mar 31 2025	n/a	n/a	US$17b
Dec 31 2024	US$23m	US$2m	US$17b
Sep 30 2024	n/a	n/a	US$12b
Jun 30 2024	n/a	n/a	US$14b
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$20m	US$2m	US$365m
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$13b
Dec 31 2022	US$19m	US$2m	US$15b
Sep 30 2022	n/a	n/a	US$15b
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b

보상 대 시장: Rob의 총 보수(USD23.19M)는 US 시장에서 비슷한 규모 기업의 평균(USD13.50M)보다 높습니다.

보상과 수익: Rob의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Rob Davis (58 yo)

4.9yrs

재임 기간

US$23,186,065

보수

Mr. Robert M. Davis, also known as Rob, J.D., is CEO & Chairman of Merck Sharp & Dohme LLC. He is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December...

리더십 팀

이름	직위	재임 기간	보수	지분
Robert Davis	Chairman	4.9yrs	US$23.19m	0.018% $ 51.5m
Caroline Litchfield	Executive VP & CFO	4.9yrs	US$7.51m	0.0037% $ 10.5m
Betty Larson	Executive VP & Chief Human Resources Officer	1.9yrs	US$11.26m	0.00025% $ 718.3k
Richard DeLuca	Executive VP & President of Merck Animal Health	14.5yrs	US$9.10m	0.0065% $ 18.6m
Dean Li	Executive VP & President of Merck Research Laboratories	8.3yrs	US$10.09m	0.0037% $ 10.7m
Dalton Smart	Senior VP of Finance	2.3yrs	데이터 없음	0.00033% $ 948.1k
David Williams	Executive VP and Chief Information & Digital Officer	no data	데이터 없음	0.0013% $ 3.6m
Peter Dannenbaum	Vice President of Investor Relations	6.6yrs	데이터 없음	데이터 없음
Jennifer Zachary	Executive VP & General Counsel	7.9yrs	US$5.90m	0.0028% $ 8.0m
Chirfi Guindo	Executive Vice President of Strategic Access	less than a year	US$13.94m	0.0024% $ 7.0m
Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	16.3yrs	US$6.24m	0.0081% $ 23.2m
Johannes Oosthuizen	Executive VP and President of Oncology & MSD International	5.2yrs	데이터 없음	0.00086% $ 2.5m

5.2yrs

평균 재임 기간

58yo

평균 나이

경험이 풍부한 관리: MRK의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.2 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Robert Davis	Chairman	4.7yrs	US$23.19m	0.018% $ 51.5m
Pamela Craig	Independent Director	10.5yrs	US$403.75k	0.000070% $ 201.1k
Patricia Russo	Independent Director	30.5yrs	US$363.75k	0.00053% $ 1.5m
Thomas Glocer	Independent Lead Director	18.3yrs	US$436.25k	0.00021% $ 603.4k
Risa Lavizzo-Mourey	Independent Director	5.8yrs	US$361.00k	0.000040% $ 114.9k
Douglas Baker	Independent Director	3.8yrs	US$350.00k	0.00065% $ 1.9m
Inge Thulin	Independent Director	8yrs	US$340.00k	0.00012% $ 344.8k
Stephen Mayo	Independent Director	5yrs	US$350.00k	0% $ 0
Kathy Warden	Independent Director	6yrs	US$350.00k	0.000020% $ 57.5k
Christine Seidman	Independent Director	6yrs	US$375.00k	0% $ 0
Paul Rothman	Independent Director	10.5yrs	US$413.75k	0% $ 0
Mary Coe	Independent Director	7yrs	US$340.00k	0% $ 0

6.5yrs

평균 재임 기간

66.5yo

평균 나이

경험이 풍부한 이사회: MRK의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.5 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/03/12 06:41
종가	2026/03/12 00:00
수익	2025/12/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서 생성에 사용된 분석 모델의 세부 정보는 저희 Github 페이지에서 확인하실 수 있으며, 보고서 사용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Merck & Co., Inc.는 49명의 분석가가 다루고 있습니다. 이 중 22명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
David Toung	Argus Research Company
Charles Butler	Barclays
Emily Field	Barclays

Merck 경영진

경영진 기준 점검 3/4

핵심 정보

최근 경영진 업데이트

Merck & Co., Inc. Announces Executive Appointments and Organizational Changes in Human Health Business

Executive VP & General Counsel notifies of intention to sell stock

Chairman recently sold US$5.6m worth of stock

Chairman notifies of intention to sell stock

Recent updates

Upcoming dividend of US$0.85 per share

Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda

Merck & Co., Inc. Announces KEYTRUDA®? (Pembrolizumab) Plus Padcev®? (enfortumab Vedotin-Ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Ejfv

Merck & Co., Inc. Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL) an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Merck & Co., Inc. Announces Executive Appointments and Organizational Changes in Human Health Business

Merck Announces Positive New Data for ENFLONSIA (Caresrovimab) for Infants and Children Under 2 Years of Age At Increased Risk for Severe Respiratory Syncytial Virus Disease over Two RSV Seasons

Merck announces Health Canada Approves KEYTRUDA SC™, a Subcutaneous Formulation of Pembrolizumab Across Multiple Cancer Indications

Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium

Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX

Executive VP & General Counsel notifies of intention to sell stock

Chairman recently sold US$5.6m worth of stock

Merck Announces Health Canada Approval of ENFLONSIA for the Prevention of RSV in Newborns and Infants

Chairman notifies of intention to sell stock

Full year 2025 earnings: EPS misses analyst expectations

Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2026

Third quarter dividend of US$0.85 announced

The Oncology Anchor: Why Merck’s 46% Discount Defies the Keytruda Cliff

Merck Declares Dividend on Common Stock for the Second-Quarter of 2026, Payable on April 7, 2026

MSD Reportedly Ends Takeover Talks with Revolution Medicines

Merck Reportedly in Talks to Buy Revolution in Up to $32 Billion Deal

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib in Combination with KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph) in Certain Patients with Advanced NSCLC

Merck Reaches Agreement with U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Merck Announces KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Merck Receives Positive EU Chmp Opinion for Expanded Use of Winrevair™? (Sotatercept) in Adults with Pulmonary Arterial Hypertension (Pah, Who* Group 1 Pulmonary Hypertension)

Upcoming dividend of US$0.85 per share

Merck (NYSE:MRK) Is Increasing Its Dividend To $0.85

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

FDA Approves Merck and KEYTRUDA (Pembrolizumab) and KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph

Third quarter dividend increased to US$0.85

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravir (Dor/Isl) in Treatment-1 Infection

Merck Declares Dividend for the First Quarter of 2026, Payable on January 8, 2026

Merck Reportedly Close on A Deal to Buy Cidara

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Adults with Heterozygous Familial Hypercholesterolemia in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Phase 3 CORALreef Lipids Trial

Merck & Co., Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Merck & Co., Inc. Updates Earnings Guidance for the Year 2025

European Commission Approves KEYTRUDA® (Pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Merck Announces Positive Topline Results from the Phase 3 LITESPARK-022 Trial in Patients with Clear Cell Renal Cell Carcinoma

Merck & Co., Inc. Receives FDA Approval For Updated Indication Of WINREVAIR In Adults With PAH

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio At AHA Scientific Sessions 2025

Merck & Co., Inc. Announces the Presentation of Findings from Systematic Review of Studies on the Ep Epiiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CapvaXIVE

Merck & Co., Inc. Announces New Long-Term Data Highlighting the Sustained Survival Benefits of Keytruda® (Pembrolizumab), Merck’s anti-PD-1 Therapy, in Treating Non-Small Cell Lung Cancer (NSCLC )

Daiichi Sankyo and Merck Demonstrate Clinically Meaningful Response Rates for Raludotatug Deruxtecan in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Merck and Eisai Announces Long-Term Follow-Up Data Continued to Show Durable Benefit of KEYTRUDA®? (Pembrolizumab) Plus LENVIMA®? (lenvatinib)

Merck & Co., Inc. Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients with Platinum-Resistant Recurrent Ovarian Cancer

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravir/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Early Stages of Disease At ESMO 2025

Merck Expands Tulisokibart Clinical Development Program with Initiation of Phase 2B Trials in Three Additional Immune-Mediated Inflammatory Diseases

Investor sentiment improves as stock rises 15%

Merck Announces Positive Results from the Phase 3 HYPERION Trial Evaluating Winrevair

FDA Approves Merck’s KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA (pembrolizumab)

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

Merck & Co., Inc. Announces Positive Results from the Phase 3 STRIDE-13 Trial Evaluating CapvaXIVE

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Upcoming dividend of US$0.81 per share

Merck & Co., Inc. Announces Positive Topline Results from the Phase 3 CORALreef Lipids Trial Evaluating the Safety and Efficacy of Enlicitide Decanoate

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Health Canada Approves KEYTRUDA for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours That Are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined with Radiotherapy with or Without Cisplatin Then as Monotherapy

Shareholders Can Be Confident That Merck's (NYSE:MRK) Earnings Are High Quality

Merck Announces Positive Topline Results from the Phase 3 KEYTRUDA Trial in Patients with Muscle-Invasive Bladder Cancer

Second quarter 2025 earnings: EPS misses analyst expectations

Merck & Co., Inc. Updates Sales Guidance for the Year 2025

First quarter dividend of US$0.81 announced

Merck Declares Fourth-Quarter 2025 Dividend, Payable on October 7, 2025

Merck & Co., Inc. to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection

Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025